Developer docs
API playgroundTry for free, no card

Search company profiles

IPS Pharma

Full company profile

uuid000fpt9

Namestring
IPS Pharma
Legal namestring
Vertical Pharma Resources Limited
Websiteurl
ips-pharma.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

IPS Pharma is a UK-headquartered pharmaceutical manufacturing company (trading name of Vertical Pharma Resources Limited) specialising in unlicensed medicines, investigational medicinal products (IMPs) for clinical trials, and hard-to-source pharmaceutical products. Operating from a cGMP-certified facility in West Molesey, Surrey, the company holds an unusually broad stack of UK regulatory authorisations — including a Manufacturer's Specials Licence, MIA(IMP) 32879, WDA(H) 32879, GPhC Pharmacy Registration, and a Home Office Controlled Drugs Licence — that collectively allow it to manufacture, certify, store, distribute, and dispense both standard specials and controlled substances under a single roof.

The company's core technology is a small-batch, flexible cGMP manufacturing platform with integrated Qualified Person (QP) release, supported by 20,000+ ready-to-manufacture formulations, validated cold chain packaging, and the 24/7 MyIPS online ordering portal with a built-in England & Wales Drug Tariff Calculator. This architecture is designed for low-volume, high-complexity work — capsule filling, tablet handling, and powder-in-bottle preparations — that large contract development and manufacturing organisations (CDMOs) typically refuse due to minimum order quantity constraints. Service lines include unlicensed medicines (Specials and Imports), clinical trial supplies (IMP and comparator sourcing, manufacturing, blinding, labelling, QP certification, storage, distribution), Special Obtains (sourcing of unusual non-pharmaceutical products), and generics. Adjacent product lines span organic medical cannabis (via the £7M+ Puro supply agreement signed July 2025) and consumer supplements (via the Cortiba Health joint venture with Lyrus Life Sciences, January 2021).

IPS Pharma runs a sales-led B2B go-to-market targeting four primary customer segments: healthcare professionals (pharmacists, dispensing doctors, consultants), pharmaceutical and biotech companies running clinical trials, pharmaceutical wholesalers, and individual patients. Distribution combines direct phone-based sales (8am–8pm GMT) staffed by NVQ 2/3-qualified pharmacy-trained personnel with the self-serve MyIPS portal, plus wholesale and clinical trial sponsor channels. Pricing is quote-based per order with 30-day payment terms for account customers; no public price list exists. Revenue mechanics mix one-time product sales (Specials, Generics, Cannabis) with professional services contracts (clinical trial supply engagements), and the business model is structurally repeat-driven through long-term relationships with UK pharmacies, wholesalers, and clinical trial sponsors.

Short descriptiontext

IPS Pharma is a UK-based cGMP-certified pharmaceutical manufacturer (Vertical Pharma Resources Ltd) specialising in unlicensed medicines, small-batch IMP manufacturing for clinical trials, and hard-to-source pharmaceuticals, serving pharmacists, dispensing doctors, pharma companies, wholesalers, and patients in the UK and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWest Molesey, United Kingdom
HQ citystring
West Molesey
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
unlicensed medicines, pharmaceutical manufacturing, clinical trial supplies, special obtains, medical cannabis distribution
Industry1 code
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Unlicensed Medicines (Specials)
TypeOne Time License
Description

Sale of bespoke unlicensed medicines manufactured to meet specific patient needs where no licensed alternative exists. These are supplied to pharmacists, dispensing doctors, and directly to patients. Revenue is generated through product sales with pricing based on formulation complexity and volume.

ips-pharma.com
2Clinical Trial Supplies
TypeProfessional Services
Description

Provision of Investigational Medicinal Products (IMP), comparators, and clinical trial materials to pharmaceutical companies, biotech organisations, and academic institutions conducting clinical trials. Services include manufacturing, labelling, QP certification, storage, and distribution.

ips-pharma.com
3Special Obtains
TypeTransaction Fee
Description

Sourcing and supplying custom, unusual, or hard-to-find non-pharmaceutical products to meet specific patient needs. Revenue generated through sourcing fees and product margins.

ips-pharma.com
4Generics
TypeOne Time License
Description

Supply of generic pharmaceutical products, particularly those not stocked by mainstream wholesalers.

ips-pharma.com
5Medical Cannabis Distribution
TypeOne Time License
Description

Import and distribution of organic medical cannabis products through the UK and European network under the supply agreement with Puro, supported by MHRA-compliant manufacturing and full quality assurance.

ips-pharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Bespoke pharmaceutical product pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing is based on individual order specifications including formulation type, quantity ordered, complexity of preparation, and regulatory compliance requirements. No standard pricing tiers are publicly listed. Quotes are provided upon request through the MyIPS portal or customer service team.

ips-pharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IPS Pharma manufactures and supplies unlicensed medicines (Specials) and Investigational Medicinal Products (IMPs) from a cGMP-certified UK facility, offering over 20,000 formulations for immediate manufacture. The company provides end-to-end clinical trial supply services including small-batch manufacturing, Qualified Person (QP) certification, labelling, storage, distribution, and special obtains sourcing for healthcare professionals, pharmaceutical companies, and patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduced waste and cost through right-sized manufacturing (vs overproduction at large CDMOs)
+3 more records
Product overview1 text field

IPS Pharma operates as a pharmaceutical services company offering a portfolio of interconnected products centered on unlicensed medicines (Specials), clinical trial supplies, and special obtains. The core offering consists of unlicensed medicines manufacturing with over 20,000 formulations, supported by clinical trial supplies including IMP manufacturing, QP certification, and distribution. Supporting services include the MyIPS online ordering portal (24/7), Drug Tariff Calculator, Early/Expanded Access Programs, Clinical Specials Offering, and Direct to Patient services. The company has also expanded into medical cannabis through a landmark Puro supply agreement, and consumer health via the Cortiba Health joint venture (Yellow Root curcumin supplements).

Product and service6 records
1Unlicensed Medicines (Specials/Imports)
CategoryUnlicensed Pharmaceutical Products
Description

Provides ethically sourced, compliant, and timely access to quality-assured unlicensed pharmaceutical products for patients with unmet clinical needs. Offers over 20,000 formulations available for immediate manufacture, supplied to pharmacists, dispensing doctors, and patients.

2Clinical Trial Supplies
CategoryClinical Trial Services
Description

Comprehensive Investigational Medicinal Product (IMP) and comparator supply services supporting global clinical trial operations. Includes small-batch manufacturing, QP certification, labelling, storage, and global distribution for pharmaceutical companies, life science and biotech firms, and academic institutions.

3Special Obtains
CategorySourcing Services
Description

Sourcing service for custom, unusual, or hard-to-find non-pharmaceutical products to meet specific and individual patient needs when standard products are unavailable.

4Generics
CategoryGeneric Pharmaceuticals
Description

Supply of generic pharmaceutical products as part of the company's broad medicines portfolio, particularly those not stocked by mainstream wholesalers.

5Puro Organic Medical Cannabis
CategoryMedical Cannabis
Description

Certified organic medical cannabis products imported from New Zealand through a £7M+ supply agreement with Puro. Includes live-dried flower with full cannabinoid and terpene profiles across five strains, distributed through UK and European clinics and pharmacies.

6Cortiba Health Yellow Root Curcumin
CategoryHealth and Wellness Supplements
Description

Joint venture brand with Lyrus Life Sciences offering organic turmeric supplements with patented C3 Cura Advanced Absorption Technology. Available in three formulations: Yellow Root + Vitamin A (immune support), Yellow Root + Vitamin D3 (joint health), and Yellow Root + Vitamin B12 (metabolic balance).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

IPS Pharma signed a £7M+ (NZ$16.1 million) supply agreement with Puro, New Zealand's leading certified organic medical cannabis producer. The agreement, signed at the New Zealand High Commission in London, brings Puro's organic, sun-grown, live-dried cannabis flower to UK and European patients. Puro's seven-stage live drying process preserves full cannabinoid and terpene profiles. The first shipment of seven pallets covering five strains arrived in the UK in March 2026. This is reportedly the largest certified organic cannabis supply deal of its kind in the world.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-14
Description

Joint venture between IPS Pharma and Lyrus Life Sciences resulting in the launch of Cortiba Health, a new brand offering health and wellness products. The first product is Yellow Root Curcumin supplements using patented C3 Cura Advanced Absorption Technology. Cortiba Health focuses on organic turmeric supplements with enhanced bioavailability formulations.

3Grow Biotech
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-04-26
Description

Grow Biotech and IPS Specials created a new joint venture company focused on import, distribution, and market access services for cannabis-based medicinal products in the UK and Europe. The new company represented the only complete UK medicinal cannabis licensed market access proposition at the time. Formation was targeted for completion before end of April 2019.

ips-pharma.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-headquartered pharmaceutical services company operating in unlicensed medicines, clinical trial supply, and specialty pharma distribution. Closest direct competitor to IPS Pharma in UK specials, early access, and IMP services.

TypeDirect peer
Description

Northern Ireland-based CDMO with strong clinical trial supply, IMP manufacturing, and QP release services. Competes with IPS Pharma for UK and European early-phase clinical trial and small-batch manufacturing work.

3BCM Specials
TypeDirect peer
Description

UK-based dedicated unlicensed medicines (Specials) manufacturer supplying pharmacists and dispensing doctors. Directly comparable to IPS Pharma's core UK Specials manufacturing business.

4Torbay Pharmaceuticals
TypeDirect peer
Description

NHS-owned UK specials manufacturer producing unlicensed medicines for hospital and community pharmacy use. Direct competitor in the UK Part VIIIB Drug Tariff specials segment.

TypeDirect peer
Description

UK pharmaceutical distributor with a heritage in supplying unlicensed, imported, and hard-to-find medicines. Overlaps directly with IPS Pharma's distribution and special obtains offerings.

6Sharp Clinical Services
TypeDirect peer
Description

Clinical trial supply services provider offering IMP manufacturing, packaging, labelling, QP release, and global distribution. Comparable to IPS Pharma's clinical trial supplies vertical.

TypeDirect peer
Description

UK-based pharma services company providing early-phase drug development, small-batch manufacturing, and clinical trial supply. Competes with IPS Pharma in early-phase and small-batch IMP services.

TypeBroad incumbent
Description

Global CDMO and clinical trial supply services provider with broad capabilities across IMP manufacturing, packaging, and distribution. Larger incumbent with overlapping but broader portfolio relative to IPS Pharma.

TypeBroad incumbent
Description

Major global CDMO offering small- and large-batch pharmaceutical manufacturing, clinical trial supply, and packaging services. A much larger incumbent with potential to move into IPS Pharma's small-batch and IMP niches.

TypeRegional player
Description

UK-based pharmaceutical distributor specialising in unlicensed, imported, and clinical trial medicines. A regional peer with overlapping distribution and clinical trial supply offerings focused on the UK.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IPS Pharma

Pharmaceutical Manufacturingips-pharma.com

IPS Pharma is a UK-based cGMP-certified pharmaceutical manufacturer (Vertical Pharma Resources Ltd) specialising in unlicensed medicines, small-batch IMP manufacturing for clinical trials, and hard-to-source pharmaceuticals, serving pharmacists, dispensing doctors, pharma companies, wholesalers, and patients in the UK and Europe.

What IPS Pharma does

IPS Pharma is a UK-headquartered pharmaceutical manufacturing company (trading name of Vertical Pharma Resources Limited) specialising in unlicensed medicines, investigational medicinal products (IMPs) for clinical trials, and hard-to-source pharmaceutical products. Operating from a cGMP-certified facility in West Molesey, Surrey, the company holds an unusually broad stack of UK regulatory authorisations — including a Manufacturer's Specials Licence, MIA(IMP) 32879, WDA(H) 32879, GPhC Pharmacy Registration, and a Home Office Controlled Drugs Licence — that collectively allow it to manufacture, certify, store, distribute, and dispense both standard specials and controlled substances under a single roof.

The company's core technology is a small-batch, flexible cGMP manufacturing platform with integrated Qualified Person (QP) release, supported by 20,000+ ready-to-manufacture formulations, validated cold chain packaging, and the 24/7 MyIPS online ordering portal with a built-in England & Wales Drug Tariff Calculator. This architecture is designed for low-volume, high-complexity work — capsule filling, tablet handling, and powder-in-bottle preparations — that large contract development and manufacturing organisations (CDMOs) typically refuse due to minimum order quantity constraints. Service lines include unlicensed medicines (Specials and Imports), clinical trial supplies (IMP and comparator sourcing, manufacturing, blinding, labelling, QP certification, storage, distribution), Special Obtains (sourcing of unusual non-pharmaceutical products), and generics. Adjacent product lines span organic medical cannabis (via the £7M+ Puro supply agreement signed July 2025) and consumer supplements (via the Cortiba Health joint venture with Lyrus Life Sciences, January 2021).

IPS Pharma runs a sales-led B2B go-to-market targeting four primary customer segments: healthcare professionals (pharmacists, dispensing doctors, consultants), pharmaceutical and biotech companies running clinical trials, pharmaceutical wholesalers, and individual patients. Distribution combines direct phone-based sales (8am–8pm GMT) staffed by NVQ 2/3-qualified pharmacy-trained personnel with the self-serve MyIPS portal, plus wholesale and clinical trial sponsor channels. Pricing is quote-based per order with 30-day payment terms for account customers; no public price list exists. Revenue mechanics mix one-time product sales (Specials, Generics, Cannabis) with professional services contracts (clinical trial supply engagements), and the business model is structurally repeat-driven through long-term relationships with UK pharmacies, wholesalers, and clinical trial sponsors.

IPS Pharma firmographics

Firmographics
Name
IPS Pharma
Legal name
Vertical Pharma Resources Limited
Website
https://ips-pharma.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
101–250 employees
Short description
IPS Pharma is a UK-based cGMP-certified pharmaceutical manufacturer (Vertical Pharma Resources Ltd) specialising in unlicensed medicines, small-batch IMP manufacturing for clinical trials, and hard-to-source pharmaceuticals, serving pharmacists, dispensing doctors, pharma companies, wholesalers, and patients in the UK and Europe.
Ownership category
akta.pro rank

IPS Pharma industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Unlicensed medicines
  • Pharmaceutical manufacturing
  • Clinical trial supplies
  • Special obtains
  • Medical cannabis distribution

Where IPS Pharma is headquartered

Location

Headquarters

HQ city
West Molesey
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

IPS Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Unlicensed Medicines (Specials): Sale of bespoke unlicensed medicines manufactured to meet specific patient needs where no licensed alternative exists. These are supplied to pharmacists, dispensing doctors, and directly to patients. Revenue is generated through product sales with pricing based on formulation complexity and volume.
  2. Clinical Trial Supplies: Provision of Investigational Medicinal Products (IMP), comparators, and clinical trial materials to pharmaceutical companies, biotech organisations, and academic institutions conducting clinical trials. Services include manufacturing, labelling, QP certification, storage, and distribution.
  3. Special Obtains: Sourcing and supplying custom, unusual, or hard-to-find non-pharmaceutical products to meet specific patient needs. Revenue generated through sourcing fees and product margins.
  4. Generics: Supply of generic pharmaceutical products, particularly those not stocked by mainstream wholesalers.
  5. Medical Cannabis Distribution: Import and distribution of organic medical cannabis products through the UK and European network under the supply agreement with Puro, supported by MHRA-compliant manufacturing and full quality assurance.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goBespoke pharmaceutical product pricing

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

IPS Pharma product offering

Product offering

Core offering

IPS Pharma manufactures and supplies unlicensed medicines (Specials) and Investigational Medicinal Products (IMPs) from a cGMP-certified UK facility, offering over 20,000 formulations for immediate manufacture. The company provides end-to-end clinical trial supply services including small-batch manufacturing, Qualified Person (QP) certification, labelling, storage, distribution, and special obtains sourcing for healthcare professionals, pharmaceutical companies, and patients.

Product overview

IPS Pharma operates as a pharmaceutical services company offering a portfolio of interconnected products centered on unlicensed medicines (Specials), clinical trial supplies, and special obtains. The core offering consists of unlicensed medicines manufacturing with over 20,000 formulations, supported by clinical trial supplies including IMP manufacturing, QP certification, and distribution. Supporting services include the MyIPS online ordering portal (24/7), Drug Tariff Calculator, Early/Expanded Access Programs, Clinical Specials Offering, and Direct to Patient services. The company has also expanded into medical cannabis through a landmark Puro supply agreement, and consumer health via the Cortiba Health joint venture (Yellow Root curcumin supplements).

Differentiator

Problem solved

Functional benefit

Products and services

  • Unlicensed Medicines (Specials/Imports) Provides ethically sourced, compliant, and timely access to quality-assured unlicensed pharmaceutical products for patients with unmet clinical needs. Offers over 20,000 formulations available for immediate manufacture, supplied to pharmacists, dispensing doctors, and patients.
  • Clinical Trial Supplies Comprehensive Investigational Medicinal Product (IMP) and comparator supply services supporting global clinical trial operations. Includes small-batch manufacturing, QP certification, labelling, storage, and global distribution for pharmaceutical companies, life science and biotech firms, and academic institutions.
  • Special Obtains Sourcing service for custom, unusual, or hard-to-find non-pharmaceutical products to meet specific and individual patient needs when standard products are unavailable.
  • Generics Supply of generic pharmaceutical products as part of the company's broad medicines portfolio, particularly those not stocked by mainstream wholesalers.
  • Puro Organic Medical Cannabis Certified organic medical cannabis products imported from New Zealand through a £7M+ supply agreement with Puro. Includes live-dried flower with full cannabinoid and terpene profiles across five strains, distributed through UK and European clinics and pharmacies.
  • Cortiba Health Yellow Root Curcumin Joint venture brand with Lyrus Life Sciences offering organic turmeric supplements with patented C3 Cura Advanced Absorption Technology. Available in three formulations: Yellow Root + Vitamin A (immune support), Yellow Root + Vitamin D3 (joint health), and Yellow Root + Vitamin B12 (metabolic balance).

Quantifiable outcome

  • Reduced waste and cost through right-sized manufacturing (vs overproduction at large CDMOs)
  • +3 more outcomes

Companies that use IPS Pharma

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

IPS Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

IPS Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship, minor and core.

  • PuroflagshipStrategic or Co-development Partner · 1 July 2025IPS Pharma signed a £7M+ (NZ$16.1 million) supply agreement with Puro, New Zealand's leading certified organic medical cannabis producer. The agreement, signed at the New Zealand High Commission in London, brings Puro's organic, sun-grown, live-dried cannabis flower to UK and European patients. Puro's seven-stage live drying process preserves full cannabinoid and terpene profiles. The first shipment of seven pallets covering five strains arrived in the UK in March 2026. This is reportedly the largest certified organic cannabis supply deal of its kind in the world.
  • Lyrus Life SciencesminorStrategic or Co-development Partner · 14 January 2021Joint venture between IPS Pharma and Lyrus Life Sciences resulting in the launch of Cortiba Health, a new brand offering health and wellness products. The first product is Yellow Root Curcumin supplements using patented C3 Cura Advanced Absorption Technology. Cortiba Health focuses on organic turmeric supplements with enhanced bioavailability formulations.
  • Grow BiotechcoreStrategic or Co-development Partner · 26 April 2019Grow Biotech and IPS Specials created a new joint venture company focused on import, distribution, and market access services for cannabis-based medicinal products in the UK and Europe. The new company represented the only complete UK medicinal cannabis licensed market access proposition at the time. Formation was targeted for completion before end of April 2019.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

IPS Pharma competitors and assessment

Company assessment

Direct peers

  • Clinigen Group: UK-headquartered pharmaceutical services company operating in unlicensed medicines, clinical trial supply, and specialty pharma distribution. Closest direct competitor to IPS Pharma in UK specials, early access, and IMP services.
  • Almac Group: Northern Ireland-based CDMO with strong clinical trial supply, IMP manufacturing, and QP release services. Competes with IPS Pharma for UK and European early-phase clinical trial and small-batch manufacturing work.
  • BCM Specials: UK-based dedicated unlicensed medicines (Specials) manufacturer supplying pharmacists and dispensing doctors. Directly comparable to IPS Pharma's core UK Specials manufacturing business.
  • Torbay Pharmaceuticals: NHS-owned UK specials manufacturer producing unlicensed medicines for hospital and community pharmacy use. Direct competitor in the UK Part VIIIB Drug Tariff specials segment.
  • Mawdsleys: UK pharmaceutical distributor with a heritage in supplying unlicensed, imported, and hard-to-find medicines. Overlaps directly with IPS Pharma's distribution and special obtains offerings.
  • Sharp Clinical Services: Clinical trial supply services provider offering IMP manufacturing, packaging, labelling, QP release, and global distribution. Comparable to IPS Pharma's clinical trial supplies vertical.
  • Quotient Sciences: UK-based pharma services company providing early-phase drug development, small-batch manufacturing, and clinical trial supply. Competes with IPS Pharma in early-phase and small-batch IMP services.

Broad incumbents

  • PCI Pharma Services: Global CDMO and clinical trial supply services provider with broad capabilities across IMP manufacturing, packaging, and distribution. Larger incumbent with overlapping but broader portfolio relative to IPS Pharma.
  • Catalent: Major global CDMO offering small- and large-batch pharmaceutical manufacturing, clinical trial supply, and packaging services. A much larger incumbent with potential to move into IPS Pharma's small-batch and IMP niches.

Regional players

  • Durbin PLC: UK-based pharmaceutical distributor specialising in unlicensed, imported, and clinical trial medicines. A regional peer with overlapping distribution and clinical trial supply offerings focused on the UK.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

IPS Pharma social profiles

Digital presence

IPS Pharma compliance and trust

Trust signal

Compliance8 records

IPS Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IPS Pharma leadership team

Management profile

Number of profiles

Profiles1 record

IPS Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

IPS Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IPS Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IPS Pharma

What does IPS Pharma do?

IPS Pharma manufactures and supplies unlicensed medicines (Specials) and Investigational Medicinal Products (IMPs) from a cGMP-certified UK facility, offering over 20,000 formulations for immediate manufacture. The company provides end-to-end clinical trial supply services including small-batch manufacturing, Qualified Person (QP) certification, labelling, storage, distribution, and special obtains sourcing for healthcare professionals, pharmaceutical companies, and patients.

Is IPS Pharma a public or private company?

IPS Pharma is a private company. It is classified as unknown and is currently operating.

When was IPS Pharma founded?

IPS Pharma was founded in 2001. It employs 101 to 250 people.

Where is IPS Pharma based?

IPS Pharma is headquartered in West Molesey, United Kingdom, in the Europe region.

How does IPS Pharma make money?

Five revenue lines are on record. Unlicensed Medicines (Specials) is the primary driver. The others are clinical Trial Supplies, special Obtains, generics and medical Cannabis Distribution.

Who are IPS Pharma's main competitors?

Direct peers on record are Clinigen Group, Almac Group, BCM Specials, Torbay Pharmaceuticals, Mawdsleys, Sharp Clinical Services and Quotient Sciences. Broad incumbents are PCI Pharma Services and Catalent. Durbin PLC is listed as a regional player.

Does IPS Pharma have an API?

No public API is recorded for IPS Pharma.

What industry is IPS Pharma in?

IPS Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireLeading U.S. Cannabis Brand Airo Launches AiroPro Inhalation System in the United KingdomAiro Brands and SOMAÍ launched the AiroPro inhalation system in the UK, with IPS Pharma as exclusive distributor. The initial portfolio includes four formulations across two collections, available through UK pharmacies. Additional products are planned for expansion.EIN PresswireLeading U.S. Cannabis Brand Airo Launches AiroPro Inhalation System in the United KingdomAiro launched its AiroPro inhalation system in the UK, with IPS Pharma as exclusive distributor. The system pairs Airo's vaporization technology with SOMAÍ's EU-GMP inhalation extracts, initially offering four formulations across two collections. Additional products are planned for expansion.PharmafileDunbar Pharmaceuticals and IPS Pharma announce distribution agreementDunbar Pharmaceuticals made its plant-derived dronabinol API, WaterClear THC, available in the UK through IPS Pharma's Specials service. The ingredient will be used in cannabis-based products for medicinal use, including capsules, oral spray, and oily solution, under the UK's Specials framework. The UK launch follows Dunbar's entry into the German market earlier this year.EIN PresswireSOMAÍ Signs Exclusive UK Agreement to Launch Globally Recognized Cannabis BrandsSOMAÍ signed an exclusive UK agreement with IPS Pharma and Integro Clinics to launch three globally recognized cannabis brands into the UK medical market. The partnership combines SOMAÍ's EU-GMP manufacturing with IPS Pharma's distribution and Integro Clinics' patient access platform. The launch aims to expand access to differentiated cannabinoid products in the UK.CannabistcompanyColumbia Care Launches First of Its Kind Medical Cannabis Capsule in UK; Provides More Precise Dosing Option and Longer Lasting Therapeutic Benefits for Physicians and PatientsColumbia Care announced it launched a proprietary solid-fill cannabis powder capsule for medicinal use in the United Kingdom, the first dose-metered medicinal cannabis product manufactured there. The patent-pending capsules, part of its Ceed range, incorporate multiple cannabinoids and offer longer-lasting effects than the UK's previous options of cannabis flower and sublingual tinctures. Manufacturing is handled by IPS Pharma, with market access support from Grow Pharma.